Baidu
map

Stroke:ACE2缺乏和氧化应激在老龄脑血管功能障碍中发挥了重要作用

2013-01-04 Stroke 互联网 geniusgodyu

血管紧张素II产生氧化应激和脑动脉内皮功能不全,血管紧张素II的I型受体可能在寿命及血管衰老中起到作用。血管紧张素转化酶2型(ACE2)将血管紧张素II转化为血管紧张素(1-7),并可对血管紧张素II的效应起保护作用。美国爱荷华州大学的Ricardo A. Pena Silva博士等人通过研究发现:ACE2缺乏损害成年鼠脑动脉内皮功能,加剧了衰老过程中内皮功能的损害。氧化应激在ACE2缺乏和衰老诱


血管紧张素II产生氧化应激和脑动脉内皮功能不全,血管紧张素II的I型受体可能在寿命及血管衰老中起到作用。血管紧张素转化酶2型(ACE2)将血管紧张素II转化为血管紧张素(1-7),并可对血管紧张素II的效应起保护作用。美国爱荷华州大学的Ricardo A. Pena Silva博士等人通过研究发现:ACE2缺乏损害成年鼠脑动脉内皮功能,加剧了衰老过程中内皮功能的损害。氧化应激在ACE2缺乏和衰老诱发的脑血管功能障碍中起到了重要的作用。相关论文发表在Stroke杂志2012年11月15日在线版上。

研究人员分别在ACE2基因敲除(KO)和野生型(WT)的成年鼠(12个月)、老年鼠(24个月)的脑动脉中检测内皮功能、血管紧张素系统成分的表达、NADPH氧化酶亚单位和促炎细胞因子。使用超氧化物清道夫tempol检验氧化应激对内皮功能的作用。

结果发现:ACE2基因敲除型鼠对乙酰胆碱产生的血管扩张作用(24±6%)相较野生型鼠(52±7%)显着受损(P<0.05)。WT老年鼠对乙酰胆碱的血管扩张作用受损(29±6%),在ACE2 KO老年鼠显着受损(7±5%)。Tempol改善成年和老年ACE2 KO和MT鼠的内皮功能。衰老增加了WT鼠肿瘤坏死因子α mRNA的表达。ACE2 KO和WT鼠中都出现了NAPDH氧化酶、p47phox和钙调神经磷酸酶1的mRNA水平都显着增加。衰老过程中血管紧张素系统成分的mRNA水平没有发生改变。

研究人员得出结论:ACE2缺乏损害成年鼠脑动脉内皮功能,加剧了衰老过程中内皮功能的损害。氧化应激在ACE2缺乏和衰老诱发的脑血管功能障碍中起到了重要的作用。


doi: 10.1161/​STROKEAHA.112.667063
PMC:
PMID:

Impact of ACE2 Deficiency and Oxidative Stress on Cerebrovascular Function With Aging

Ricardo A. Peña-Silva, MD, PhD, Yi Chu, PhD, Jordan D. Miller, PhD, Ian J. Mitchell, BSc, Josef M. Penninger, MD, Frank M. Faraci, PhD and Donald D. Heistad, MD

Background and Purpose—Angiotensin II produces oxidative stress and endothelial dysfunction in cerebral arteries, and angiotensin II type I receptors may play a role in longevity and vascular aging. Angiotensin-converting enzyme type 2 (ACE2) converts angiotensin II to angiotensin (1–7) and thus, may protect against effects of angiotensin II. We hypothesized that ACE2 deficiency increases oxidative stress and endothelial dysfunction in cerebral arteries and examined the role of ACE2 in age-related cerebrovascular dysfunction. Methods—Endothelial function, expression of angiotensin system components, NADPH oxidase subunits, and proinflammatory cytokines were examined in cerebral arteries from adult (12 months old) and old (24 months old) ACE2 knockout (KO) and wild-type (WT) mice. The superoxide scavenger tempol was used to examine the role of oxidative stress on endothelial function. Results—Vasodilatation to acetylcholine was impaired in adult ACE2 KO (24±6% [mean±SE]) compared with WT mice (52±7%; P<0.05). In old mice, vasodilatation to acetylcholine was impaired in WT mice (29±6%) and severely impaired in ACE2 KO mice (7±5%). Tempol improved endothelial function in adult and old ACE2 KO and WT mice. Aging increased mRNA for tumor necrosis factor-α in WT mice, and significantly increased mRNA levels of NAPDH oxidase 2, p47phox, and Regulator of calcineurin 1 in both ACE2 KO and WT mice. mRNA levels of angiotensin system components did not change during aging. Conclusions—ACE2 deficiency impaired endothelial function in cerebral arteries from adult mice and augmented endothelial dysfunction during aging. Oxidative stress plays a critical role in cerebrovascular dysfunction induced by ACE2 deficiency and aging.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023453, encodeId=f4a0202345399, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 10 15:26:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655663, encodeId=251d1655663fe, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Jun 23 22:26:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382987, encodeId=27a6138298e1a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420979, encodeId=cfe514209e93a, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445076, encodeId=d37b14450e690, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511954, encodeId=a7ea1511954db, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023453, encodeId=f4a0202345399, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 10 15:26:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655663, encodeId=251d1655663fe, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Jun 23 22:26:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382987, encodeId=27a6138298e1a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420979, encodeId=cfe514209e93a, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445076, encodeId=d37b14450e690, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511954, encodeId=a7ea1511954db, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
    2013-06-23 shanyongle
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023453, encodeId=f4a0202345399, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 10 15:26:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655663, encodeId=251d1655663fe, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Jun 23 22:26:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382987, encodeId=27a6138298e1a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420979, encodeId=cfe514209e93a, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445076, encodeId=d37b14450e690, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511954, encodeId=a7ea1511954db, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2023453, encodeId=f4a0202345399, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 10 15:26:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655663, encodeId=251d1655663fe, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Jun 23 22:26:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382987, encodeId=27a6138298e1a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420979, encodeId=cfe514209e93a, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445076, encodeId=d37b14450e690, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511954, encodeId=a7ea1511954db, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2023453, encodeId=f4a0202345399, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 10 15:26:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655663, encodeId=251d1655663fe, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Jun 23 22:26:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382987, encodeId=27a6138298e1a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420979, encodeId=cfe514209e93a, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445076, encodeId=d37b14450e690, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511954, encodeId=a7ea1511954db, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2023453, encodeId=f4a0202345399, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 10 15:26:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655663, encodeId=251d1655663fe, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Jun 23 22:26:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382987, encodeId=27a6138298e1a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420979, encodeId=cfe514209e93a, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445076, encodeId=d37b14450e690, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511954, encodeId=a7ea1511954db, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jan 06 05:26:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]

相关资讯

Stroke:大的卒中单元能够提高卒中治疗效果并缩短住院时间

专门的卒中单元能够改善卒中患者的预后,但是尚没有哪种临床评分系统能够评价大量患者的治疗花费及临床预后。丹麦Aarhus大学医院的Marie Louise Svendsen 博士等进行研究发现:相较而言,大的卒中单元(收治病人数多的卒中单元)救治患者能够提高救治质量、缩短住院时间、减少费用。相关论文发表在stroke杂志2012年9月13日在线版上。 研究人员在全国范围内人群为基础的队列研究中纳入

Stroke:心理因素与卒中发生相关

       一项新研究发现,抑郁、紧张或对生活不满的老年人罹患卒中及死于卒中的风险升高。该研究显示,与心理社会痛苦水平最低的人相比,痛苦水平最高的人罹患卒中的风险显著升高,并且卒中死亡风险高达后者3倍。该研究于12月13日在线发表于《卒中》杂志。        该研究研究者美国明尼阿波利斯市明尼苏达大学医学副教

Stroke:抗血小板药物和降压药物能降低无症状性颈动脉狭窄患者的卒中风险

最新的证据提示现有最好的药物治疗可能足以预防无症状性颈动脉狭窄患者卒中的发生。如果真是这样的,那么确定治疗所降低的风险就显得至关重要。为此,英国圣乔治大学卒中与痴呆研究中心的Alice King博士等人进行了一项研究,研究结果在线发表在2012年11月27日的Stroke杂志上。结果发现:抗血小板治疗和血压控制是降低无症状颈动脉狭窄患者短期卒中和心血管风险的最重要因素。 该研究为无症状性颈动脉栓

Stroke:未破裂颅内动脉瘤夹闭后的MR-DWI阳性病灶数有助预测症状性缺血并发症

未破裂颅内动脉瘤夹闭后症状性缺血并发症(症状性缺血并发症SIC、短暂性脑缺血发作或卒中)、微血栓(根据MR的弥散加权图像,即MR-DWI阳性进行判断)的危险因素,以及MR-DWI阳性,即DWI(+)与SIC之间的关系尚不明确。为此,韩国Yonsei医学院Severance医院影像科的Byung Moon Kim博士等人进行了一项研究,研究结果在线发表在2012年11月29日的Stroke杂志上。研

Stroke:脑血管再灌注有待进一步发展

早期再灌注对急性脑缺血和急性心肌缺血都是最有效的治疗方法。但是头颈部循环床为再通的干预提出了更大的挑战。再灌注的历史性发展情况之前还没有出现过系统性比较。为此,美国加州大学David Geffen医学院神经科的Jeffrey L. Saver等人进行了一项研究,研究结果在线发表在2012年11月27日的Stroke杂志上。研究结果发现:脑缺血相对心脏缺血的再灌注治疗发展更慢,效果也更差。需要脑血管

Stroke:研究发现西欧国家近几十年来脑卒中死亡率下降而发病率增高

在西欧,过去几十年里缺血性卒中的死亡率显着下降。年龄性别特异性缺血性卒中的死亡、缺血性卒中发病率、发病后30天病死率和住院后1年死亡率是用来描述新千年里缺血性卒中死亡率改变趋势的重要指标。为了检验缺血性卒中的死亡率和发病率之间的匹配情况,荷兰乌德勒支医学中心Julius生命科学和初级救护中心的IloncaVaartjes博士等人进行了一项研究,研究结果在线发表在2012年12月4日的Stroke杂

Baidu
map
Baidu
map
Baidu
map